Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Covid

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Sep 17, 2021 6:36pm

95 Views

Post# 33882090

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Covid

Sacloco wrote: To be honest I already did short it as soon as the consolidation happened, quite significantly as well and more than doubled my money. Probably wait for another quick pump from the board, wait for the price to spike then ride it down again. But who knows. I appreciate the recommendation tho...

Good for you! Thanks for the honesty. Keep shorting it, will you. And use next time an even higher amount, so you can triple or quadruple your money

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!